ATE534649T1 - Imidazothiazole und imidazoxazolderivative als inhibitoren von p38 - Google Patents

Imidazothiazole und imidazoxazolderivative als inhibitoren von p38

Info

Publication number: ATE534649T1
Authority: AT; Austria
Prior art keywords: imidazoxazole; imidazothiazoles; inhibitors; derivatives; inhibiting
Prior art date: 2003-05-15

Application number

AT04752390T

Other languages

English (en)

Inventor

Mark Ashwell

Syed Ali

Jifeng Liu

Yanbin Liu

Peter Lohse

Belew Mekonnen

Robert Selliah

Manish Tandon

Woj Wrona

Valery Antonenko

Original Assignee

Arqule Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-05-15

Filing date

2004-05-14

Publication date

2011-12-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33555294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE534649(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-05-14 Application filed by Arqule Inc filed Critical Arqule Inc

2011-12-15 Application granted granted Critical

2011-12-15 Publication of ATE534649T1 publication Critical patent/ATE534649T1/de

Links

239000003112 inhibitor Substances 0.000 title 1
102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 abstract 3
230000000694 effects Effects 0.000 abstract 2
230000002401 inhibitory effect Effects 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
102000004127 Cytokines Human genes 0.000 abstract 1
108090000695 Cytokines Proteins 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
238000000338 in vitro Methods 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Oncology (AREA)
Physical Education & Sports Medicine (AREA)
Communicable Diseases (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Molecular Biology (AREA)
Orthopedic Medicine & Surgery (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Tropical Medicine & Parasitology (AREA)
Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
AIDS & HIV (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Vascular Medicine (AREA)

AT04752390T 2003-05-15 2004-05-14 Imidazothiazole und imidazoxazolderivative als inhibitoren von p38 ATE534649T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US47073503P	2003-05-15	2003-05-15
US51229803P	2003-10-17	2003-10-17
PCT/US2004/015368 WO2004110990A2 (en)	2003-05-15	2004-05-14	Imidazothiazoles and imidazoxazole derivatives as inhibitors of p38

Publications (1)

Publication Number	Publication Date
ATE534649T1 true ATE534649T1 (de)	2011-12-15

Family

ID=33555294

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04752390T ATE534649T1 (de)	2003-05-15	2004-05-14	Imidazothiazole und imidazoxazolderivative als inhibitoren von p38

Country Status (9)

Country	Link
US (2)	US7902192B2 (de)
EP (2)	EP1633758B1 (de)
JP (1)	JP4939220B2 (de)
KR (1)	KR20060025141A (de)
AT (1)	ATE534649T1 (de)
AU (1)	AU2004247626B8 (de)
CA (1)	CA2526285A1 (de)
MX (1)	MXPA05012377A (de)
WO (1)	WO2004110990A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0308466D0 (en) *	2003-04-11	2003-05-21	Novartis Ag	Organic compounds
US7902192B2 (en)	2003-05-15	2011-03-08	Arqule, Inc.	Inhibitors of P38 and methods of using the same
TWI326282B (en)	2004-04-28	2010-06-21	Mitsubishi Tanabe Pharma Corp	Heterocyclic compound
EP2258704A1 (de)	2004-10-19	2010-12-08	ArQule, Inc.	Synthese aus Imidazooxazol- und Imidazothiazol-hemmern der P38-map-kinase
WO2007123892A2 (en) *	2006-04-17	2007-11-01	Arqule Inc.	Raf inhibitors and their uses
RS52062B (sr) *	2006-05-19	2012-06-30	Abbott Laboratories	Cns aktivni azabiciklični alkanski derivati koji su supstituisani spojenim bicikloheterociklom
EP1992344A1 (de)	2007-05-18	2008-11-19	Institut Curie	P38 Alpha als therapeutisches Target für Erkrankungen, die mit einer FGFR3- Mutation assoziiert sind
CN101801937A (zh)	2007-06-22	2010-08-11	艾科尔公司	喹唑啉酮化合物及其使用方法
WO2009005675A1 (en)	2007-06-28	2009-01-08	Abbott Laboratories	Novel triazolopyridazines
JP4792128B2 (ja)	2007-10-12	2011-10-12	アークルインコーポレイテッド	癌に対するｈｓｐ９０阻害剤としての５−（２−ヒドロキシフェニル）テトラゾール
US8067409B2 (en) *	2007-11-27	2011-11-29	Abbott Laboratories	Protein kinase inhibitors
BRPI0921862A2 (pt)	2008-12-05	2015-12-29	Arqule Inc	inibidores de raf e seus usos
EP2432767B1 (en) *	2009-05-19	2013-06-26	Dow AgroSciences LLC	Compounds and methods for controlling fungi
GB201321731D0 (en) *	2013-12-09	2014-01-22	Ucb Pharma Sa	Therapeutic agents
US11332479B2 (en)	2016-07-05	2022-05-17	Korea Institute Of Science And Technology	Imidazooxazole derivative having antitumor effect, and pharmaceutical composition including same
KR101948805B1 (ko)	2016-07-05	2019-02-15	한국과학기술연구원	항종양 효과를 갖는 이미다조옥사졸 유도체 및 이를 포함하는 약학적 조성물
JP7377207B2 (ja)	2018-01-29	2023-11-09	メルクパテントゲーエムベーハー	Ｇｃｎ２阻害剤およびその使用
EP4616913A3 (de) *	2018-01-29	2025-12-10	Merck Patent GmbH	Gcn2-inhibitoren und verwendungen davon
CN113121564A (zh) *	2019-12-31	2021-07-16	韩国科学技术研究院	具有抗肿瘤效果的咪唑并恶唑衍生物及包括其的药物组合物
WO2025101004A1 (ko) *	2023-11-08	2025-05-15	한양대학교 에리카산학협력단	6-aryl imidazo[2,1-b]thi/oxazole-2-carboxilic acid 유도체 및 이를 유효성분으로 함유하는 알츠하이머병 치료용 약학 조성물

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3455924A (en)	1967-02-08	1969-07-15	Upjohn Co	Dianisylimidazoles
JPS61214793A (ja)	1985-03-15	1986-09-24	Citizen Watch Co Ltd	Ｆｄｄ駆動用サ−ボ制御回路
US4794114A (en)	1986-08-19	1988-12-27	Smithkline Beckman Corporation	Inhibition of interleukin-1 production by monocytes and/or macrophages
US4892578A (en)	1987-11-06	1990-01-09	Fmc Corporation	Phenylmethyl-4,4-dimethyl-3-isoxazolidinone plant regulators
WO1991000092A1 (en)	1989-06-13	1991-01-10	Smithkline Beecham Corporation	Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages
AU7629594A (en)	1993-07-21	1995-02-20	Smithkline Beecham Corporation	Imidazoles for treating cytokine mediated disease
US5869043A (en)	1993-09-17	1999-02-09	Smithkline Beecham Corporation	Drug binding protein
US5783664A (en)	1993-09-17	1998-07-21	Smithkline Beecham Corporation	Cytokine suppressive anit-inflammatory drug binding proteins
AU686669B2 (en)	1993-09-17	1998-02-12	Smithkline Beecham Corporation	Drug binding protein
US6090626A (en)	1994-05-31	2000-07-18	Isis Pharmaceuticals Inc.	Antisense oligonucleotide modulation of raf gene expression
US6410518B1 (en)	1994-05-31	2002-06-25	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide inhibition of raf gene expression
US5747498A (en)	1996-05-28	1998-05-05	Pfizer Inc.	Alkynyl and azido-substituted 4-anilinoquinazolines
WO1997032604A1 (en)	1996-03-07	1997-09-12	Novartis Ag	Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds
JP2000504023A (ja)	1996-04-03	2000-04-04	メルクエンドカンパニーインコーポレーテッド	癌治療方法
US6147080A (en)	1996-12-18	2000-11-14	Vertex Pharmaceuticals Incorporated	Inhibitors of p38
US6376214B1 (en)	1997-02-18	2002-04-23	Smithkline Beecham Corporation	DNA encoding a novel homolog of CSBP/p38 MAP kinase
US6187799B1 (en)	1997-05-23	2001-02-13	Onyx Pharmaceuticals	Inhibition of raf kinase activity using aryl ureas
US6344476B1 (en)	1997-05-23	2002-02-05	Bayer Corporation	Inhibition of p38 kinase activity by aryl ureas
ES2153337T3 (es)	1997-05-23	2008-11-01	Bayer Pharmaceuticals Corporation	Inhibidores de la quinasa raf.
US5994412A (en)	1997-07-10	1999-11-30	Merck & Co., Inc.	Bis-aryl ethers, compositions containing such compounds and methods of treatment
CA2306870A1 (en)	1997-10-20	1999-04-29	David Michael Goldstein	Bicyclic kinase inhibitors
EP1049664B1 (de)	1997-12-22	2005-03-16	Bayer Pharmaceuticals Corporation	Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen
HUP0101704A3 (en)	1997-12-22	2002-12-28	Bayer Corp Pittsburgh	Kinease substituted heterocyclic ureas with raf inhibition activity and pharmaceutical compositions containing them
SK285371B6 (sk)	1997-12-22	2006-12-07	Bayer Corporation	Aryl- a heteroaryl-substituované heterocyklické močoviny, ich použitie a farmaceutické kompozície sich obsahom
US6683100B2 (en)	1999-01-19	2004-01-27	Novartis Ag	Organic compounds
US6162613A (en)	1998-02-18	2000-12-19	Vertex Pharmaceuticals, Inc.	Methods for designing inhibitors of serine/threonine-kinases and tyrosine kinases
US6302838B1 (en)	1998-02-25	2001-10-16	Novartis Ag	Cancer treatment with epothilones
AU772477B2 (en)	1998-08-28	2004-04-29	Scios Inc.	Inhibitors of p38-alpha kinase
AR023659A1 (es)	1998-09-18	2002-09-04	Vertex Pharma	Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos
AU3114600A (en)	1998-12-16	2000-07-03	Vertex Pharmaceuticals Incorporated	Crystallized p38 complexes
US8124630B2 (en)	1999-01-13	2012-02-28	Bayer Healthcare Llc	ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1140840B1 (de)	1999-01-13	2006-03-22	Bayer Pharmaceuticals Corp.	-g(v)-carboxyaryl substituierte diphenyl harnstoffe als raf kinase inhibitoren
US7351834B1 (en)	1999-01-13	2008-04-01	Bayer Pharmaceuticals Corporation	ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7928239B2 (en)	1999-01-13	2011-04-19	Bayer Healthcare Llc	Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
SK16482001A3 (sk)	1999-05-21	2002-04-04	Scios Inc.	Indolové deriváty ako inhibítory p38 kinázy
US6689883B1 (en)	1999-09-28	2004-02-10	Bayer Pharmaceuticals Corporation	Substituted pyridines and pyridazines with angiogenesis inhibiting activity
UA74803C2 (uk)	1999-11-11	2006-02-15	Осі Фармасьютікалз, Інк.	Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US6437147B1 (en)	2000-03-17	2002-08-20	Novo Nordisk	Imidazole compounds
AU2001270783B2 (en)	2000-07-11	2006-06-15	Pharma Mar, S.A.	Variolin derivatives as anti-cancer agents
US7235576B1 (en)	2001-01-12	2007-06-26	Bayer Pharmaceuticals Corporation	Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1247810B1 (de)	2001-04-04	2005-09-07	Pfizer Products Inc.	Neue Benzotriazole mit entzündungshemmender Wirkung
WO2002083628A1 (en)	2001-04-13	2002-10-24	Boehringer Ingelheim Pharmaceuticals, Inc.	1,4-disubstituted benzo-fused compounds
ATE355272T1 (de)	2001-04-20	2006-03-15	Bayer Pharmaceuticals Corp	Inhibierung der raf-kinase durch chinolin-, isochinolin- oder pyridin-harnstoffe
US20030207914A1 (en)	2001-04-20	2003-11-06	Bayer Corporation	Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
CA2450555A1 (en)	2001-06-25	2003-01-03	Merck & Co., Inc.	(pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
GB0124848D0 (en)	2001-10-16	2001-12-05	Celltech R&D Ltd	Chemical compounds
AU2002351196A1 (en)	2001-12-03	2003-06-17	Bayer Pharmaceuticals Corporation	Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
AU2002365899B2 (en)	2001-12-04	2007-09-13	Onyx Pharmaceuticals, Inc.	RAF-MEK-ERK pathway inhibitors to treat cancer
US20030207872A1 (en)	2002-01-11	2003-11-06	Bayer Corporation	Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2003068223A1 (en)	2002-02-11	2003-08-21	Bayer Corporation	Aryl ureas with raf kinase and angiogenesis inhibiting activity
US20030216396A1 (en)	2002-02-11	2003-11-20	Bayer Corporation	Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
SI1580188T1 (sl)	2002-02-11	2012-02-29	Bayer Healthcare Llc	Aril sečnine kot kinazni inhibitorji
US8299108B2 (en)	2002-03-29	2012-10-30	Novartis Ag	Substituted benzazoles and methods of their use as inhibitors of raf kinase
ATE447404T1 (de)	2002-03-29	2009-11-15	Novartis Vaccines & Diagnostic	Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
WO2003087087A2 (en)	2002-04-09	2003-10-23	Astex Technology Limited	Heterocyclic compounds and their use as modulators of p38 map kinase
WO2003102139A2 (en)	2002-05-29	2003-12-11	Uab Research Foundation	Erbin as a negative regulator of ras-raf-erk signaling
JP2006504667A (ja)	2002-08-08	2006-02-09	ベーリンガーインゲルハイムファーマシューティカルズインコーポレイテッド	炎症過程に関与するサイトカインの抑制剤としてのフッ素化フェニル−ナフタレニル−尿素化合物
ATE402700T1 (de)	2002-08-27	2008-08-15	Merck Patent Gmbh	Glycinamid-derivate als raf-kinase-hemmer
CA2503445C (en)	2002-10-24	2012-07-31	Merck Patent Gesellschaft Mit Beschraenkter Haftung	Methylene urea derivatives as raf-kinase inhibitors
RU2350611C1 (ru)	2002-12-24	2009-03-27	Астразенека Аб	Производные фосфонооксихиназолина и их фармацевтическое применение
DE10306250A1 (de)	2003-02-14	2004-09-09	Aventis Pharma Deutschland Gmbh	Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP1603566B1 (de)	2003-03-11	2009-01-21	Novartis AG	Verwendung von isochinolin-derivaten zur behandlung von krebs und erkrankungen im zusammenhang mit map kinase
MXPA05010020A (es)	2003-03-24	2005-11-17	Merck Patent Gmbh	Derivados de oxamida.
US20070129281A1 (en)	2003-04-02	2007-06-07	Carr Robin A E	Pharmaceutical compounds
GB0308511D0 (en)	2003-04-14	2003-05-21	Astex Technology Ltd	Pharmaceutical compounds
US7902192B2 (en)	2003-05-15	2011-03-08	Arqule, Inc.	Inhibitors of P38 and methods of using the same
MXPA06002853A (es)	2003-09-11	2006-06-14	Kemia Inc	Inhibidores citoquina.
WO2006010082A1 (en)	2004-07-08	2006-01-26	Arqule, Inc.	1,4-disubstituted naphtalenes as inhibitors of p38 map kinase
EP2258704A1 (de)	2004-10-19	2010-12-08	ArQule, Inc.	Synthese aus Imidazooxazol- und Imidazothiazol-hemmern der P38-map-kinase
JP4801096B2 (ja)	2005-01-19	2011-10-26	ライジェルファーマシューティカルズ，インコーポレイテッド	２，４−ピリミジンジアミン化合物のプロドラッグおよびそれらの使用
WO2007123892A2 (en)	2006-04-17	2007-11-01	Arqule Inc.	Raf inhibitors and their uses
GB0609617D0 (en)	2006-05-16	2006-06-21	Astrazeneca Ab	Process & intermediate
GB0609621D0 (en)	2006-05-16	2006-06-21	Astrazeneca Ab	Novel co-crystal

2004
- 2004-05-14 US US10/556,161 patent/US7902192B2/en not_active Expired - Fee Related
- 2004-05-14 EP EP04752390A patent/EP1633758B1/de not_active Expired - Lifetime
- 2004-05-14 EP EP10175256A patent/EP2251343A1/de not_active Withdrawn
- 2004-05-14 JP JP2006533130A patent/JP4939220B2/ja not_active Expired - Lifetime
- 2004-05-14 CA CA002526285A patent/CA2526285A1/en not_active Abandoned
- 2004-05-14 AT AT04752390T patent/ATE534649T1/de active
- 2004-05-14 AU AU2004247626A patent/AU2004247626B8/en not_active Ceased
- 2004-05-14 MX MXPA05012377A patent/MXPA05012377A/es active IP Right Grant
- 2004-05-14 KR KR1020057021750A patent/KR20060025141A/ko not_active Ceased
- 2004-05-14 WO PCT/US2004/015368 patent/WO2004110990A2/en not_active Ceased
2010
- 2010-12-03 US US12/960,079 patent/US20110301160A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20110301160A1 (en)	2011-12-08
AU2004247626B8 (en)	2011-05-19
EP1633758B1 (de)	2011-11-23
CA2526285A1 (en)	2004-12-23
WO2004110990A3 (en)	2005-03-24
EP1633758A2 (de)	2006-03-15
JP4939220B2 (ja)	2012-05-23
WO2004110990A2 (en)	2004-12-23
AU2004247626B2 (en)	2011-01-20
KR20060025141A (ko)	2006-03-20
AU2004247626A1 (en)	2004-12-23
US7902192B2 (en)	2011-03-08
MXPA05012377A (es)	2006-05-25
JP2006528983A (ja)	2006-12-28
US20070270418A1 (en)	2007-11-22
EP2251343A1 (de)	2010-11-17

Publication	Publication Date	Title
DE60315146D1 (de)	2007-09-06	Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase
DE60334651D1 (de)	2010-12-02	Nicotinamide und deren Verwendung als P38 Inhibitoren
ATE406351T1 (de)	2008-09-15	Kondensierte heteroyralderivate zur verwendung als p38-kinase-inhibitoren
ATE521608T1 (de)	2011-09-15	Glucokinaseaktivatoren
ATE435015T1 (de)	2009-07-15	Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
NO20013341D0 (no)	2001-07-05	Fenylfenantridiner med PDE-IV inhiberende aktivitet
DE60314500D1 (de)	2007-08-02	Diaminopyrimidine und deren verwendung als angiogenesehemmer
EP1481077A4 (de)	2006-01-11	Mitotische kinesin-hemmer
MY140132A (en)	2009-11-30	Thiazolidin-4-one derivatives for use in the treatment of anemias
ATE494904T1 (de)	2011-01-15	Verbindungen und verfahren zur erhöhung der neurogenese
DE602006008643D1 (de)	2009-10-01	Ophthalmische Zusammensetzungen von parasympathischen Stimulantia und Entzündungshemmer zur Verwendung bei der Behandlung von Presbyopie
DE602004014117D1 (de)	2008-07-10	Thiazole zur verwendung als inhibitoren von protein-kinasen
TW200700422A (en)	2007-01-01	Compounds for inhibiting ksp kinesin activity
ATE413392T1 (de)	2008-11-15	Kondensierte heteroyralderivate und deren verwendung als p38-kinase-inhibitoren
DE602005021894D1 (de)	2010-07-29	Triazolophthalazine
WO2004110990A3 (en)	2005-03-24	Imidazothiazoles and imidazoxazole derivatives as inhibitors of p38
ATE446753T1 (de)	2009-11-15	Verwendung von substituierten 2-thio-3,5-dicyano- 4-phenyl-6-aminopyridinen bei der behandlung von übelkeit und erbrechen
ATE421501T1 (de)	2009-02-15	2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck
BRPI0509660A (pt)	2007-10-09	compostos de beta-carbolina de utilidade no tratamento de doenças inflamatórias
ATE460923T1 (de)	2010-04-15	Lyophilisierung von virosomen
TW200700066A (en)	2007-01-01	Compounds for inhibiting ksp kinesin activity
ATE343582T1 (de)	2006-11-15	Derivate von (6, 7-dihydro -5h-imidazo(1,2 - a)imidazol -3 -sulfonylamino)-propionamid und deren verwendung als inhibitoren der interaktion von cams und leukointreginen
DE502005007105D1 (de)	2009-05-28	4-amino-5-oxo-8-phenyl-5h-pyrido-ä2,3-dü-pyrimidin-derivate als inhibitoren der tyrosinkinasen und der raf-kinasen zur behandlung von tumoren
BRPI0415038A (pt)	2006-12-12	derivados de imidazo (4,5-b) piridina como inibidores sem ser da sintase que podem ser induzidos
ATE309701T1 (de)	2005-12-15	Verwendung von riboflavin und flavinderivaten als inhibitoren von chitinasen